Premium
Pharmacokinetics of Single and Multiple Infusions of 5S Intravenous Immunoglobulin
Author(s) -
Theobald Klaus,
Högy Barbara
Publication year - 1995
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1995.tb02536.x
Subject(s) - pharmacokinetics , intravenous infusions , medicine , antibody , intravenous immunoglobulins , intravenous use , intravenous drug , pharmacology , anesthesia , immunology , human immunodeficiency virus (hiv) , viral disease
A prospective, open and uncontrolled trial was performed to investigate the pharmacokinetics of a 5S intravenous immunoglobulin (IVIG) after single and multiple infusions. Twelve healthy volunteers received a 5S‐IVIG enriched in antibodies against Staphylococcus areus α‐toxin (aSAT) either as a single infusion or as three infusions in daily intervals. The fate of the injected immunoglobulin was observed by serial measurements of the serum level of aSAT titres. The 5S‐IVIG had a half‐life with a median of 0.24 (distribution) and 2.0 (terminal) days, respectively. The pharmacokinetic parameters did not differ with dose groups or number of applications. The study medication was well tolerated.